Oxidative Stress & Cardiovascular Disease

Product name

Big Endothelin

Range0 – 3 pmol/l
Sensitivity0.10 pmol/l
Incubation time5.5 hours
Sample volume50 µl
Sample type

Serum, plasma

Sample preparation

Centrifuge freshly collected blood within one day.
Samples should be stored at -20°C, for long time storage store at -70°C. Maximum 4 freeze-thaw cycles.

Reference values

Serum: Median: 0.09 pmol/l (n= 41)


Human, porcine & rat

Cross reaction
ET1/2/3 (1-21) <1%
ET2 (1-37) <1%
ET1/2 (1-38) <1%
pig Big ET (1-39) 21%
Big ET-1/2 (22-38) <1%
Big ET-2 (22-37) <1%
Sarafotoxin  <1%
rat Big ET-1 (1-39) 10%


Intended use

Big Endothelin-1 (Big ET), a small 38-amino-acid peptide, is a biological precursor of Endothelin (1-21), the most potent vasoconstrictor known today. Various cell types including vascular endothelial cells and non-vascular cells (eg. Mesangial, kidney and epithelial cells) produce Endothelin.
Cleavage of Big Endothelin by a membrane-bound metalloproteinase, the Endothelin Converting Enzyme, leads to the active Endothelin (1-21) and to the biological inactive C-terminal fragment (22-38).
The physiological importance of cleavage of Big Endothelin is indicated by the reported 140-fold increase in vasoconstrictor activity upon cleavage to Endothelin-1, although both peptides can be determined in about equimolar concentrations in plasma.
Both Big ET and ET are strong independent predictors of survival in patients with congestive heart
failure, and identify a population with a very high risk mortality.
It was demonstrated that the half-life of Endothelin (1-21) in the plasma is less than one minute, whereas clearance of Big Endothelin is is much slower. BigET can therefore be determined more easily.


Clinical significance:

  • prognostic value in heart failure and acute myocardial infarction
  • renal insufficiency
  • during an after graft rejection
  • atherosclerosis
  • pulmonary hypertension
  • scleroderma


Product informations

Back to overview